TTS Australia 2018 seeks to present a suite of topics relevant to the Tech Transfer industry. To view the full program, please click on the button below
- Translational research as a key driver for innovation in Biotech and Healthcare
- Engaging with the NIH
- What makes a successful tech transfer professional?
- Successful product development for medical devices
- Update on the Biomedical translation fund
- Alternative sources of funding and investment
- Big Pharma
Steven Ferguson - NIH
Steven Ferguson will present on 'Engaging the NIH. Building productive and sustainable academic collaborations for advancing innovation in Australia.' Steven currently serves as the Deputy Director, Licensing and Entrepreneurship at the NIH.
Prior to joining NIH Office of Technology Transfer in 1990, Mr. Ferguson served in marketing and management positions in biomedical firms subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital. Registered to practice before the USPTO and a Certified Licensing Professional (CLP),
Mr Ferguson also holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor’s Degree in Chemistry (Case Western Reserve University). Mr. Ferguson has been an economic reviewer for Maryland Industrial Partnerships (MIPS) as well as the Advanced Technology Program (ATP) grant programs and is an instructor for both the USDA Graduate School and the NIH FAES Graduate School where he is also the department chair for the new Certificate in Technology Transfer Program. Mr Ferguson was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory and has published articles on licensing and technology transfer issues.
Tony Hickson - Imperial Innovations
Tony will present on 'From IP to ecosystems - the evolution of Imperial Innovations'. Tony Hickson BSc, MBA, CLP, RTTP is Managing Director of Imperial Innovations and an Executive Director on the board of Touchstone Innovations plc.
Tony is responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Prior to joining the company in 2002, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group, Murex Biotech, Abbott Laboratories and Kalibrant Limited.
He has been a board director or observer for a number of start-up companies including Emcision, Polytherics (now Abzena) and Catapult Therapy TCR Limited, and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014) and Cell Medica (in advanced clinical studies). Tony is a Certified Licensing Professional, a board director of PraxisUnico and until recently acted as Chairman of the Intellectual Property Board of the European Institute of Technology Climate Change KIC.
Dr Dimitri A Vinarov - McDonnell Boehnen Hulbert & Berghoff
Dr Dimitriy A Vinarov will present on ‘the fun with IP clauses in agreements as part of global strategies to enable your business model, financing and deal-making'. As Equity Partner of MBHB, Dr Vinarov’s practice encompasses primarily all phases of US and foreign patent prosecution, with an emphasis on pharmaceuticals, biologicals, diagnostics, biochemistry, cell biology, immunology, molecular biology, medical devices, and diagnostics.
Dr Vinarov also provides client counseling in the areas of patentability, freedom-to-operate, infringement, and validity analyses. Dr Vinarov’s client list includes Fortune 100 companies, mid-size companies, startups, and academic institutions.
Prior to joining MBHB, Dr. Vinarov spent nearly ten years leading the development and commercialization of the cell-free protein expression technology at the Center for Eukaryotic Structural Genomics at the University of Wisconsin-Madison, Ehime University in Matsuyama, Japan, and the CellFree Sciences Co. in Yokohama, Japan. Dr. Vinarov also served as a scientific and business consultant to a variety of companies in the U.S., U.K., and Japan.